You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
甘李藥業(603087.SH):上半年淨利潤同比預增100.73%到114.12%

格隆匯7月9日丨甘李藥業(603087.SH)公佈2025年半年度業績預增公告,預計2025年半年度實現歸屬於母公司所有者的淨利潤爲6億元到6.4億元,同比增加100.73%到114.12%。公司預計2025年半年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤爲4.6億元至5億元,同比增加262.47%到293.99%。

2025年上半年,公司實現歸屬於母公司所有者的淨利潤較去年同期大幅增長,主要受益於營業收入的顯著提升及公司費用的精細化管控。通過兩輪胰島素集採,公司成功實現擴大市場份額的戰略目標。尤其在2024年接續集採中,協議量較上次集採大幅增長32.6%,同時產品價格合理回升,形成量價齊升的協同效應。2025年上半年,公司藉助集採獲得的市場覆蓋優勢,深耕各層級市場,產品銷量增長顯著。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account